J&J Unit To Pay $5.9M To End Mont. Risperdal Row

Law360, New York (March 10, 2014, 5:46 PM EDT) -- A Johnson & Johnson unit on Thursday agreed to pay $5.9 million to resolve a suit brought by Montana's attorney general claiming the company promoted its antipsychotic drug Risperdal as safe despite knowing it posed risks of health problems including diabetes.

Janssen Pharmaceutical Inc. agreed to the settlement without admitting to any wrongdoing, as part of a deal that prevents it from misleading consumers about its drugs in the future, according to a statement by the Montana AG’s office.

Roughly $1.5 million of the settlement funds...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.